Literature DB >> 36224320

Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE.

Dongmei Wang1, Yongming Wu1, Yue Pan1, Shengnan Wang1, Guanghui Liu1, Yibo Gao2,3,4,5, Kaibiao Xu6.   

Abstract

New-onset refractory status epilepticus (NORSE) is rare but intractable. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and cryptogenic etiologies are the two major causes of NORSE with distinct clinical features. To elucidate the underlying mechanisms, 6 patients with anti-NMDAR encephalitis NORSE and 5 with cryptogenic NORSE (C-NORSE) were enrolled. Five patients of cerebrovascular disorders were used as controls. Quantitative proteomic analysis of the cerebrospinal fluid (CSF) samples of the patients revealed 101 and 56 proteins were changed, respectively. The average fold-change of the upregulated proteins, namely up-proteomic score in this study, was positively correlated with the severity and prognosis of the diseases, including ICU stay (r = 0.9308, P = 0.0035 in NMDAR group; r = 0.8977, P = 0.0193 in C-NORSE group), mRS score at discharge (r = 0.9710, P = 0.0111 in NMDAR group; r = 0.7071, P = 0.2000 in C-NORSE group), and time taken for patients awaking from a coma (r = 0.8823, P = 0.0100 in NMDAR group; r = 0.7906, P = 0.2000 in C-NORSE group). Pathways involved in humoral immune response, wound healing, and epigenetic regulation of transcription were upregulated in anti-NMDAR encephalitis NORSE. Pathways of innate and lymphocyte mediated immune response, synaptic functions, ubiquitination, and cell apoptosis were up-regulated in C-NORSE, which was consistent with a mouse model of status epilepticus. Fc receptor and B cell mediated immunity signaling pathways were downregulated in C-NORSE. Immunome microarray analysis demonstrated high autoantibody targeting 48 proteins in CSF samples of anti-NMDAR encephalitis NORSE. While the reaction was kept at a very low level in C-NORSE. There is no significant difference in inflammatory cytokine level between each group. The level of IL-4 (r = 0.7435, P = 0.0451), IL-13 (r = 0.7643, P = 0.0384), IFN-γ (r = 0.7973, P = 0.0287) and TNF-α (r = 0.8598, P = 0.0141) in NMDAR group, and IL-6 (r = 0.8479, P = 0.0348), IL-8 (r = 0.9076, P = 0.0166) in C-NORSE group were positively correlated with the up-proteomic score. The present study suggests that the up-proteomic score of CSF could be a promising indicator for assessment of the severity of anti-NMDAR encephalitis NORSE and C-NORSE. The distinct CSF proteomes imply different pathogenic mechanisms of the two diseases, and immunotherapy strategies as well.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anti-NMDAR encephalitis; Cerebrospinal fluid proteome; Cryptogenic-NORSE; Immune response; Neurodegeneration; Status epilepticus

Year:  2022        PMID: 36224320     DOI: 10.1007/s12035-022-03011-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  33 in total

Review 1.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

2.  New-onset refractory status epilepticus: Etiology, clinical features, and outcome.

Authors:  Nicolas Gaspard; Brandon P Foreman; Vincent Alvarez; Christian Cabrera Kang; John C Probasco; Amy C Jongeling; Emma Meyers; Alyssa Espinera; Kevin F Haas; Sarah E Schmitt; Elizabeth E Gerard; Teneille Gofton; Peter W Kaplan; Jong W Lee; Benjamin Legros; Jerzy P Szaflarski; Brandon M Westover; Suzette M LaRoche; Lawrence J Hirsch
Journal:  Neurology       Date:  2015-08-21       Impact factor: 9.910

Review 3.  Molecular mechanisms of epilepsy.

Authors:  Kevin Staley
Journal:  Nat Neurosci       Date:  2015-02-24       Impact factor: 24.884

Review 4.  Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.

Authors:  Lawrence J Hirsch; Nicolas Gaspard; Andreas van Baalen; Rima Nabbout; Sophie Demeret; Tobias Loddenkemper; Vincent Navarro; Nicola Specchio; Lieven Lagae; Andrea O Rossetti; Sara Hocker; Teneille E Gofton; Nicholas S Abend; Emily J Gilmore; Cecil Hahn; Houman Khosravani; Felix Rosenow; Eugen Trinka
Journal:  Epilepsia       Date:  2018-02-05       Impact factor: 5.864

5.  Is rat hippocampus section immunostaining an indicator for immunotherapy in cryptogenic adult new-onset refractory status epilepticus (NORSE)?

Authors:  Dongmei Wang; Yue Pan; Kaibin Huang; Zhenzhou Lin; Zuoshan Xie; Guanghui Liu; Yongming Wu; Shengnan Wang
Journal:  Seizure       Date:  2020-02-04       Impact factor: 3.184

6.  Plasma exchange in cryptogenic new onset refractory status epilepticus.

Authors:  Judy Li; Christina Saldivar; Rama K Maganti
Journal:  Seizure       Date:  2012-10-12       Impact factor: 3.184

7.  Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy.

Authors:  Claire R E Gall; Odai Jumma; Rajiv Mohanraj
Journal:  Seizure       Date:  2013-01-18       Impact factor: 3.184

Review 8.  New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.

Authors:  Nicolas Gaspard; Lawrence J Hirsch; Claudine Sculier; Tobias Loddenkemper; Andreas van Baalen; Judette Lancrenon; Michel Emmery; Nicola Specchio; Raquel Farias-Moeller; Nora Wong; Rima Nabbout
Journal:  Epilepsia       Date:  2018-02-24       Impact factor: 5.864

9.  Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy.

Authors:  Takahiro Iizuka; Naomi Kanazawa; Juntaro Kaneko; Naomi Tominaga; Yutaka Nonoda; Atsuko Hara; Yuya Onozawa; Hiroki Asari; Takashi Hata; Junya Kaneko; Kenji Yoshida; Yoshihiro Sugiura; Yoshikazu Ugawa; Masashi Watanabe; Hitomi Tomita; Arifumi Kosakai; Atsushi Kaneko; Daisuke Ishima; Eiji Kitamura; Kazutoshi Nishiyama
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.